New Discoveries Reveal Further Connections Between the Gut Microbiome, Human Health, and Rare Diseases
geralt / Pixabay

New Discoveries Reveal Further Connections Between the Gut Microbiome, Human Health, and Rare Diseases

According to a story from bioengineer.org, a team of researchers associated with Oregon State University are making further headway in understanding the connection between our health and the bacteria that…

Continue Reading New Discoveries Reveal Further Connections Between the Gut Microbiome, Human Health, and Rare Diseases
First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease
Free-Photos / Pixabay

First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease

Do you have ADPKD? If you or someone you know has ADPKD, email us at [email protected]. We'd love to hear from you about your experience! According to a story from…

Continue Reading First Patient Enrolled in Phase 3 Trial for Autosomal Dominant Polycystic Kidney Disease

The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

  In the mid-1980s the FDA was criticized for being slow in approving new drugs. In fact, a commission was formed as a result of the mounting criticism. Janet Woodcock,…

Continue Reading The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

Phase 2 Clinical Trial for Microvillus Inclusion Disease Approved to Begin in Turkey

MVID Microvillus inclusion disease (MVID) is a rare, gastrointestinal disease which can cause impaired development in children. It is characterized by severe diarrhea which leads to dehydration and malnutrition. MVID…

Continue Reading Phase 2 Clinical Trial for Microvillus Inclusion Disease Approved to Begin in Turkey

Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment

According to a story from globenewswire.com, the genetic medicines company Homology Medicines, Inc. has recently announced that it has opened enrollment for its phase 1/2 clinical trial. This clinical trial…

Continue Reading Phase 1/2 Trial for an Experimental Phenylketonuria Gene Therapy Has Begun Enrollment
ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
HeungSoon / Pixabay

ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial

According to a story from Ysios Capital, the biotechnology company Minoryx Therapeutics recently announced that the first patient has been dosed in the company's phase 2 clinical trial. This trial…

Continue Reading ICYMI: First Patient is Dosed in Phase 2 Friedreich’s Ataxia Trial
Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
source: pixabay.com

Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients

According to a story from mdmag.com, a recent study that was presented at the 2019 meeting of the American Society of Clinical Oncology has demonstrated the potential of a two…

Continue Reading Immunotherapy Elicits Positive Response in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients
Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation
Free-Photos / Pixabay

Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

According to a story from Acrofan, the biopharmaceutical company SpringWorks Therapeutics, Inc. has recently announced the that company's experimental product candidate PD-0325901 has earned Fast Track designation from the US…

Continue Reading Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

Novel Finding Could Lead to the Development of a “Resistance-Proof” Antiviral Drug

A recent study published in PLOS Biology has shown a promising new vulnerability within human viruses which could lead to the development of a new antiviral drug. This study was…

Continue Reading Novel Finding Could Lead to the Development of a “Resistance-Proof” Antiviral Drug

ICYMI: Gene Therapy That Could Make β-Thalassemia Patients Transfusion Independent Receives Marketing Authorization in EU

Transfusion-Dependent β-Thalassemia (TDT) Transfusion-dependent β-thalassemia (TDT) is a rare disease that is caused by a mutated β-globin gene. This mutation causes the amount of hemoglobin in the body to be…

Continue Reading ICYMI: Gene Therapy That Could Make β-Thalassemia Patients Transfusion Independent Receives Marketing Authorization in EU
Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug
stevepb / Pixabay

Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug

According to a press release from Danish biopharmaceutical company Orphazyme, the Company intents to proceed with a marketing authorisation application (MAA) for its experimental Niemann-Pick disease type C treatment arimoclomol.…

Continue Reading Orphazyme Preps to File European Marketing Application for Experimental Niemann-Pick disease Type C Drug